Submit a Letter to the Editor
Citation Information: J Clin Invest. 1970;49(1):78-86. https://doi.org/10.1172/JCI106225.
Abstract
A method has been devised which is free of many of the shortcomings of serial epithyroid counting techniques as an index of the rate of thyroid hormone secretion. By means of this method, the effect of treatment with Lugol's iodine on the rate of thyroidal secretion of thyroxine (T4) has been assessed in eight patients with thyrotoxicosis due to diffuse or multinodular goiter. The technique involves administration of a tracer dose of inorganic 125I followed several days later by an intravenous tracer dose of 131I-labeled T4. Serial observations of serum protein-bound (PB) 125I and 131I are accompanied by frequent measurements of endogenous serum T4 (T4-127I) concentration. Regardless of whether or not its administration was anteceded and accompanied by the administration of large doses of methimazole, iodine induced a rapid decrease in serum T4-127I concentration which could not be explained by an increase in the peripheral turnover of T4, as judged from the metabolism of the 131I-labeled hormone. Hence, the decreased serum T4 concentration could only have resulted from decreased secretion of the hormone by the gland. Analyses of specific activity relationships between PB125I or T4-127I and PB131I made possible estimations of the extent to which iodine had decreased the rate of secretion of T4. From such analysis, and in view of other considerations, it is concluded that the rapid decrease in T4 secretion induced by iodine is not the result of an acute, sustained inhibition of T4 synthesis, but rather results from an abrupt decrease in the fractional rate of thyroidal T4 release.
Authors
Leonard Wartofsky, Bernard J. Ransii, Sidney H. Ingbar
Guidelines: The Editorial Board will only consider letters that we deem relevant and of interest to our readers. We will not post data that have not been subjected to peer review, nor will we post letters that are essentially a reiteration of another letter. We reserve the right to edit any letter for length, content, and clarity. Authors will be notified by e-mail if their letters were accepted. No appeals will be considered.
Specific requirements: All letters must be 400 words or fewer. You may enter the letter as plain text or HTML. The author's name and e-mail address are required, and will be posted with the letter. All possible conflicts of interest must be noted, even if they are not posted. If you wish to include a figure (keep in mind that non-peer-reviewed data will not be posted), please contact the editors directly at editors@the-jci.org.
Copyright © 2020 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)